JP2018526970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526970A5 JP2018526970A5 JP2017563328A JP2017563328A JP2018526970A5 JP 2018526970 A5 JP2018526970 A5 JP 2018526970A5 JP 2017563328 A JP2017563328 A JP 2017563328A JP 2017563328 A JP2017563328 A JP 2017563328A JP 2018526970 A5 JP2018526970 A5 JP 2018526970A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- amino acid
- antibody
- binding
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 125000000539 amino acid group Chemical group 0.000 claims 18
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 14
- 238000006467 substitution reaction Methods 0.000 claims 13
- 235000004279 alanine Nutrition 0.000 claims 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172264P | 2015-06-08 | 2015-06-08 | |
| NL2014935 | 2015-06-08 | ||
| NL2014935A NL2014935B1 (en) | 2015-06-08 | 2015-06-08 | T cell receptor like antibodies having fine specificity. |
| US62/172,264 | 2015-06-08 | ||
| PCT/IL2016/050599 WO2016199140A1 (en) | 2015-06-08 | 2016-06-08 | T cell receptor like antibodies having fine specificity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526970A JP2018526970A (ja) | 2018-09-20 |
| JP2018526970A5 true JP2018526970A5 (enExample) | 2019-07-11 |
| JP7013243B2 JP7013243B2 (ja) | 2022-01-31 |
Family
ID=54325627
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563331A Active JP6912392B2 (ja) | 2015-06-08 | 2016-06-08 | 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用 |
| JP2017563328A Active JP7013243B2 (ja) | 2015-06-08 | 2016-06-08 | 微細特異性を有する親和性結合体 |
| JP2021113633A Active JP7147018B2 (ja) | 2015-06-08 | 2021-07-08 | 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用 |
| JP2022150286A Active JP7376655B2 (ja) | 2015-06-08 | 2022-09-21 | 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用 |
| JP2023183842A Ceased JP2024016092A (ja) | 2015-06-08 | 2023-10-26 | 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563331A Active JP6912392B2 (ja) | 2015-06-08 | 2016-06-08 | 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021113633A Active JP7147018B2 (ja) | 2015-06-08 | 2021-07-08 | 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用 |
| JP2022150286A Active JP7376655B2 (ja) | 2015-06-08 | 2022-09-21 | 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用 |
| JP2023183842A Ceased JP2024016092A (ja) | 2015-06-08 | 2023-10-26 | 高親和性および微細特異性を有するｔｃｒ様抗体結合ドメインを含む親和性結合体ならびにその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11001642B2 (enExample) |
| EP (4) | EP3302537A1 (enExample) |
| JP (5) | JP6912392B2 (enExample) |
| KR (2) | KR20180011275A (enExample) |
| CN (4) | CN114605547B (enExample) |
| AU (3) | AU2016276555B2 (enExample) |
| CA (3) | CA2988270A1 (enExample) |
| ES (1) | ES2922236T3 (enExample) |
| IL (3) | IL256178B2 (enExample) |
| MX (3) | MX2017015928A (enExample) |
| NL (1) | NL2014935B1 (enExample) |
| SG (1) | SG10202007398PA (enExample) |
| WO (2) | WO2016199140A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211754T1 (hr) | 2014-12-23 | 2022-03-04 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| MA45004A (fr) * | 2015-10-09 | 2019-03-27 | Immatics Biotechnologies Gmbh | Anticorps spécifiques anti-wt1-hla |
| AU2016342041B2 (en) | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
| JP7303750B2 (ja) * | 2017-01-24 | 2023-07-05 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物 |
| WO2018200585A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and secondary effectors and uses thereof |
| EP3635000A4 (en) * | 2017-05-16 | 2021-04-14 | The Johns Hopkins University | Manabodies and methods of using |
| JP2020523985A (ja) * | 2017-05-31 | 2020-08-13 | 科済生物医薬（上海）有限公司Ｃａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．，Ｌｔｄ． | 細胞免疫治療の組成物及び方法 |
| ES2991091T3 (es) * | 2017-06-05 | 2024-12-02 | Univ Mie | Proteína de unión a antígeno que reconoce el péptido derivado de MAGE-A4 |
| MX2019015053A (es) * | 2017-06-14 | 2020-02-13 | Adicet Bio Inc | Anticuerpos capaces de unirse a hla-a2/tyrd de forma restringida por hla y usos de estos. |
| CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
| CN111527107B (zh) * | 2017-12-21 | 2024-10-01 | 豪夫迈·罗氏有限公司 | 结合hla-a2/wt1的抗体 |
| US20200399377A1 (en) * | 2018-02-23 | 2020-12-24 | Abexxa Biologics Inc. | Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen |
| GB201803750D0 (en) * | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
| CN112424601A (zh) * | 2018-04-04 | 2021-02-26 | 豪夫迈·罗氏有限公司 | 检测癌症患者中肿瘤抗原的诊断性测定法 |
| JP2021528382A (ja) * | 2018-06-04 | 2021-10-21 | エーピーオー‐ティー ビー．ヴイ． | 免疫エフェクター細胞を腫瘍細胞へ誘引する方法及び手段 |
| US11939381B2 (en) * | 2018-07-19 | 2024-03-26 | Eli Lilly And Company | Bispecific antibodies targeting immune checkpoints |
| AU2019327490A1 (en) * | 2018-08-30 | 2021-03-25 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| KR20210087458A (ko) | 2018-10-01 | 2021-07-12 | 아디셋 바이오, 인크. | 고형 종양 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법 |
| EA202190926A1 (ru) | 2018-10-01 | 2021-06-25 | Эдисет Био, Инк. | Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей |
| KR20210134091A (ko) * | 2019-01-29 | 2021-11-08 | 그릿스톤 바이오, 인코포레이티드 | 다중특이적 결합 단백질 |
| WO2020194195A1 (en) * | 2019-03-25 | 2020-10-01 | University Health Network | T cell receptors and methods of use thereof |
| GB201904328D0 (en) * | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| WO2020257288A2 (en) * | 2019-06-18 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Mage-a4 t cell receptors and methods of use thereof |
| CN114174345B (zh) * | 2019-07-24 | 2024-11-26 | 瑞泽恩制药公司 | 具有mage-a4特异性的嵌合抗原受体和其用途 |
| US12480958B2 (en) | 2019-08-13 | 2025-11-25 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:MHC binding polypeptides |
| CN112442119B (zh) * | 2019-09-05 | 2023-02-24 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2的高亲和力t细胞受体 |
| CN110563804A (zh) * | 2019-09-19 | 2019-12-13 | 河南省农业科学院 | 基于天然免疫库筛选识别氧氟沙星单链抗体的多肽序列及应用 |
| NL2024375B1 (en) * | 2019-12-04 | 2021-08-31 | Apo T B V | Methods and means for attracting immune effector cells to tumor cells. |
| PE20221282A1 (es) * | 2019-12-18 | 2022-09-05 | Hoffmann La Roche | Anticuerpos que se unen a hla-a2/mage-a4 |
| MX2022013898A (es) | 2020-05-05 | 2023-02-09 | Regeneron Pharma | Car que comprende cd28 zeta y cd3 zeta. |
| JP2023527293A (ja) * | 2020-05-19 | 2023-06-28 | アムジエン・インコーポレーテツド | Ｍａｇｅｂ２結合構築物 |
| IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
| EP4304725A1 (en) * | 2021-03-09 | 2024-01-17 | CDR-Life AG | Rabbit-derived antigen binding protein nucleic acid libraries |
| JP2024509910A (ja) | 2021-03-09 | 2024-03-05 | シーディアール－ライフ・アクチェンゲゼルシャフト | Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質 |
| AU2022271212A1 (en) * | 2021-05-04 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| JP2024546589A (ja) * | 2021-12-14 | 2024-12-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｌａ－ａ２／ｍａｇｅ－ａ４×ｃｄ３二重特異性抗体及び４－１ｂｂ（ｃｄ１３７）アゴニストを使用したがんの治療 |
| KR20250067130A (ko) | 2022-09-14 | 2025-05-14 | 씨디알-라이프 아게 | Mage-a4 펩티드 이중 t 세포 연결체 |
| TW202513802A (zh) * | 2023-09-22 | 2025-04-01 | 美商再生元醫藥公司 | 獲得與多肽－ｍｈｃ界面結合的抗體分子之方法 |
| GB202315181D0 (en) * | 2023-10-03 | 2023-11-15 | Immunocore Ltd | Peptide-HLA binding molecules |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US8258260B2 (en) | 1970-02-11 | 2012-09-04 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4289747A (en) | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| JP2874751B2 (ja) | 1986-04-09 | 1999-03-24 | ジェンザイム・コーポレーション | 希望する蛋白質をミルク中へ分泌する遺伝子移植動物 |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| EP0857176A1 (en) | 1995-10-25 | 1998-08-12 | Centocor B.V. | HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE |
| AU5992999A (en) | 1998-10-02 | 2000-04-26 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| US7157091B1 (en) * | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| US7521202B2 (en) | 1999-12-17 | 2009-04-21 | The Board Of Regents Of The University Of Oklahoma | Method and apparatus for the production of soluble MHC antigens and uses thereof |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| US20090062512A1 (en) | 2000-10-10 | 2009-03-05 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
| US20070099182A1 (en) | 2000-10-10 | 2007-05-03 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
| US20070026433A1 (en) | 2001-03-09 | 2007-02-01 | Hildebrand William H | Epitope testing using soluble HLA |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| DE10313819A1 (de) | 2003-03-24 | 2004-10-07 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US7488793B2 (en) | 2003-09-22 | 2009-02-10 | Ludwig Institute For Cancer Research | Isolated peptide which binds to HLA-Cw*07 and uses thereof |
| DE602005011617D1 (de) | 2004-05-19 | 2009-01-22 | Medigene Ltd | Hochaffiner ny-eso-t-zellen-rezeptor |
| DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| GB0411773D0 (en) | 2004-05-26 | 2004-06-30 | Avidex Ltd | Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex |
| US20100068186A1 (en) | 2004-05-26 | 2010-03-18 | Avidex Limited | High affinity telomerase t cell receptors |
| US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| DE602004019215D1 (de) | 2004-10-02 | 2009-03-12 | Immatics Biotechnologies Gmbh | Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden |
| TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| US8378074B2 (en) | 2005-04-01 | 2013-02-19 | Immunocore Limited | High affinity HIV T cell receptors |
| EP1717245B1 (en) | 2005-04-26 | 2011-06-08 | Immatics Biotechnologies GmbH | T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof |
| GB0524477D0 (en) | 2005-11-30 | 2006-01-11 | Avidex Ltd | Isolated T cell receptors which specifically bind to vygfvracl-hla-24 |
| GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| PL1760088T3 (pl) | 2005-09-05 | 2008-10-31 | Immatics Biotechnologies Gmbh | Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA) |
| CA2630023A1 (en) * | 2005-11-14 | 2007-05-18 | Universite Laval | Cancer antigen mage-a9 and uses thereof |
| WO2007143104A2 (en) * | 2006-06-01 | 2007-12-13 | Receptor Logic, Ltd. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US20100158927A1 (en) | 2007-03-29 | 2010-06-24 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| WO2009015841A1 (en) | 2007-07-27 | 2009-02-05 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| BRPI0813621A2 (pt) | 2007-07-27 | 2017-05-09 | Immatics Biotechnologies Gmbh | imunoterapia contra tumores neuronais e cerebrais |
| CN105566450A (zh) | 2007-07-27 | 2016-05-11 | 伊玛提克斯生物技术有限公司 | 免疫疗法的新型免疫抗原表位 |
| WO2009026117A2 (en) | 2007-08-16 | 2009-02-26 | Glaxo Group Limited | Novel compounds |
| WO2009090651A2 (en) | 2008-01-15 | 2009-07-23 | Technion Research And Development Foundation Ltd. | Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis |
| SI2113253T1 (sl) | 2008-04-30 | 2010-06-30 | Immatics Biotechnologies Gmbh | Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| US20120077696A1 (en) | 2009-03-15 | 2012-03-29 | Technion Research And Development Foundation Ltd. | Soluble hla complexes for use in disease diagnosis |
| JP2012521761A (ja) | 2009-03-25 | 2012-09-20 | アルター・バイオサイエンス・コーポレーション | Ｈｉｖｖｐｒ−特異的ｔ細胞受容体 |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| CN102812043A (zh) | 2009-11-19 | 2012-12-05 | 新加坡国立大学 | 用于制备t细胞受体样单克隆抗体的方法及其用途 |
| WO2011073215A2 (en) | 2009-12-14 | 2011-06-23 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201019331D0 (en) | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
| CA2798120A1 (en) * | 2010-04-30 | 2011-11-03 | Paul P. Tamburini | Antibodies having reduced immunogenicity in a human |
| EP3778642A1 (en) * | 2010-12-27 | 2021-02-17 | Apo-T B.V. | A polypeptide that binds aberrant cells and induces apoptosis |
| CA2826942C (en) | 2011-02-11 | 2021-08-03 | Memorial Sloan-Kettering Cancer Center | Hla-restricted, peptide-specific antigen binding proteins |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| JP6082997B2 (ja) * | 2011-04-01 | 2017-02-22 | メモリアル スローン−ケタリング キャンサー センター | Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体 |
| EP2802356A1 (en) | 2012-01-13 | 2014-11-19 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
| GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
| EP3066131A1 (en) | 2013-11-07 | 2016-09-14 | Memorial Sloan-Kettering Cancer Center | Fc-enhanced anti-wt1/hla antibody |
| JP6553069B2 (ja) | 2013-11-07 | 2019-07-31 | メモリアル スローン ケタリング キャンサー センター | 抗ｗｔ１／ｈｌａ二重特異性抗体 |
| KR102721595B1 (ko) | 2015-04-03 | 2024-10-23 | 유레카 쎄라퓨틱스, 인코포레이티드 | Afp 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| US20180179283A1 (en) | 2015-06-08 | 2018-06-28 | Adicet Bio Inc. | T cell receptor like antibodies having fine specificity |
| MX2019015053A (es) | 2017-06-14 | 2020-02-13 | Adicet Bio Inc | Anticuerpos capaces de unirse a hla-a2/tyrd de forma restringida por hla y usos de estos. |
-
2015
- 2015-06-08 NL NL2014935A patent/NL2014935B1/en active
-
2016
- 2016-06-08 CA CA2988270A patent/CA2988270A1/en active Pending
- 2016-06-08 AU AU2016276555A patent/AU2016276555B2/en not_active Ceased
- 2016-06-08 MX MX2017015928A patent/MX2017015928A/es unknown
- 2016-06-08 CN CN202210349590.3A patent/CN114605547B/zh active Active
- 2016-06-08 SG SG10202007398PA patent/SG10202007398PA/en unknown
- 2016-06-08 WO PCT/IL2016/050599 patent/WO2016199140A1/en not_active Ceased
- 2016-06-08 EP EP16734763.2A patent/EP3302537A1/en not_active Withdrawn
- 2016-06-08 IL IL256178A patent/IL256178B2/en unknown
- 2016-06-08 EP EP24193198.9A patent/EP4488293A3/en active Pending
- 2016-06-08 JP JP2017563331A patent/JP6912392B2/ja active Active
- 2016-06-08 JP JP2017563328A patent/JP7013243B2/ja active Active
- 2016-06-08 EP EP16739266.1A patent/EP3302538B1/en active Active
- 2016-06-08 AU AU2016276556A patent/AU2016276556C1/en not_active Ceased
- 2016-06-08 KR KR1020177037826A patent/KR20180011275A/ko not_active Ceased
- 2016-06-08 WO PCT/IL2016/050600 patent/WO2016199141A2/en not_active Ceased
- 2016-06-08 CN CN201680039192.4A patent/CN107847569A/zh active Pending
- 2016-06-08 CA CA3220475A patent/CA3220475A1/en active Pending
- 2016-06-08 EP EP22154188.1A patent/EP4039270A1/en active Pending
- 2016-06-08 MX MX2017015801A patent/MX394431B/es unknown
- 2016-06-08 ES ES16739266T patent/ES2922236T3/es active Active
- 2016-06-08 US US15/579,616 patent/US11001642B2/en active Active
- 2016-06-08 CA CA2987889A patent/CA2987889A1/en active Pending
- 2016-06-08 CN CN202210030010.4A patent/CN114437217B/zh active Active
- 2016-06-08 KR KR1020187000504A patent/KR20180012851A/ko not_active Ceased
- 2016-06-08 CN CN201680040163.XA patent/CN108025045B/zh active Active
-
2017
- 2017-12-06 MX MX2022009493A patent/MX2022009493A/es unknown
- 2017-12-07 IL IL256177A patent/IL256177A/en unknown
-
2021
- 2021-05-11 US US17/317,824 patent/US12252547B2/en active Active
- 2021-07-08 JP JP2021113633A patent/JP7147018B2/ja active Active
-
2022
- 2022-09-21 JP JP2022150286A patent/JP7376655B2/ja active Active
- 2022-11-11 AU AU2022268398A patent/AU2022268398A1/en not_active Abandoned
-
2023
- 2023-07-30 IL IL304821A patent/IL304821A/en unknown
- 2023-10-26 JP JP2023183842A patent/JP2024016092A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526970A5 (enExample) | ||
| MY197854A (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| IL292094B2 (en) | Neoantigens and methods for using them | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| EP4296673A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
| BR112013004266A2 (pt) | anticorpos anti-ox40 e métodos de uso dos mesmos. | |
| JP2017501728A5 (enExample) | ||
| JP2019516665A5 (enExample) | ||
| WO2011063003A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
| WO2018085469A3 (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
| JP2017508475A5 (enExample) | ||
| WO2016199140A8 (en) | T cell receptor like antibodies having fine specificity | |
| AR080027A1 (es) | Proteinas de union a cd127 | |
| TN2018000325A1 (en) | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALL Y BINDING TO CD3 AND/OR CD123. | |
| JP2012143232A5 (enExample) | ||
| JP2015535816A5 (enExample) | ||
| JP2006522319A (ja) | 抗原エピトープの同定 | |
| UA114108C2 (uk) | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання | |
| EP4171751A2 (en) | Mhc multimer expression constructs and uses thereof | |
| US20230282304A1 (en) | Off-target prediction method for antigen-recognition molecules binding to mhc-peptide targets | |
| JP2014502961A5 (enExample) | ||
| WO2021116470A3 (en) | Recombinant peptide-mhc complex binding proteins and their generation and use | |
| TW202120925A (zh) | 肽：mhc結合多肽的表徵方法 | |
| JP2017538412A5 (enExample) |